Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A second-generation, non-structure protein (ns3/4a) protease inhibitor has been approved by the FDA for the treatment of chronic hepatitis C infection.

Pharmacology Update: Simeprevir Capsules (Olysio™)